Abstract
The antiepileptic drug, felbamate, was tested in a rat model of painful peripheral neuropathy (the chronic constriction injury model). Intraperitoneal doses of 150, 300 and 600 mg/kg were given to animals with established heat-hyperalgesia, mechanohyperalgesia, mechano-allodynia and signs of spontaneous pain (hindpaw guarding). Postinjection tests were conducted 2, 6, 12, 24 and 48 h later. The 150 mg/kg dose had little or no effect on any measure. Significant reductions in all measures of abnormal pain were seen after the 300 and 600 mg/kg doses; relief lasted 2 to 12 h. Side effects were trivial or absent by 2 h postinjection. Felbamate's actions were generally antihyperalgesic and antiallodynic, rather than analgesic, in that the responsiveness of the control (sham-operated) hindpaw was unaffected. We conclude that felbamate suppresses neuropathic pain sensations and that its effectiveness may be due to multiple mechanisms of action. The recently discovered severe side-effect liability of felbamate is likely to preclude its clinical application.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|